The war on drug prices continues to intensify. Recent formulary decisions demonstrated the willingness of payers to take a hard line against perceived pricing excesses. Moving forward, pricing pressure will only increase.

One therapeutic area that’s a proxy for where this drug price war is headed is oncology, and more specifically, immuno-oncology (I-O). While only a handful of I-O drugs are currently on the market, their introduction has already galvanized budgetary concerns and pricing resistance. Published in BioPharm International, The Evolving War on Drug Prices by Mike Kuchenreuther provides insight into current challenges and emerging trends likely to impact market access and pricing for I-O drugs and potentially other drug classes as well.